Methods of using (+)-1,4-dihydro-7-[(3S,4S)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-OXO-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid for treatment of antecedent hematologic disorders
US9724338B2 · kind B2 · utility
1Cited by
13References
6Claims
0Family size
Assignee
Inventor
Key dates
| Filing date | Oct 17, 2014 |
| Grant date | Aug 8, 2017 |
| Priority date | — |
| Expiry date | Oct 17, 2034 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K2039/54
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Methods of treating, preventing or managing antecedent hematologic disorders, such as myelodysplastic syndrome, including chronic myelomonocytic leukemia are disclosed. The methods encompass the administration of SNS-595. Also provided are methods of treatment using this compound with chemotherapy, radiation therapy, hormonal therapy, biological therapy or immunotherapy. In certain embodiments, the method of treatment comprise administering SNS-595 in combination with cytarabine. Pharmaceutical compositions and single unit dosage forms suitable for use in the methods are also disclosed.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.